Abstract
Adoptive transfer of antigen-specific T cells is an attractive means to provide cancer patients with immune cells of a desired specificity and the efficacy of such adoptive transfers has been demonstrated in several clinical trials. Because the T cell receptor is the single specificity-determining molecule in T cell function, adoptive transfer of TCR genes into patient T cells may be used as an alternative approach for the transfer of tumor-specific T cell immunity. On theoretical grounds, TCR gene therapy has two substantial advantages over conventional cellular transfer, as it can circumvent the demanding process of in vitro generation of large numbers of specific immune cells and it allows the use of a set of particularly effective TCR genes in large patient groups. Conversely, TCR gene therapy may be associated with a number of specific problems that are not confronted during classical cellular therapy. Here we review our current understanding of the potential and possible problems of TCR gene therapy, as based on in vitro experiments and mouse model systems. Furthermore, we discuss the prospects of clinical application of this gene therapy approach, and the possible barriers on the route towards clinical use.
Keywords: T cell receptor (TCR), adoptive therapy, gene therapy, T lymphocytes, major histocompatibility complex (MHC)
Current Gene Therapy
Title: Prospects and Limitations of T Cell Receptor Gene Therapy
Volume: 5 Issue: 6
Author(s): Miriam Coccoris, Moniek A. de Witte and Ton. N.M. Schumacher
Affiliation:
Keywords: T cell receptor (TCR), adoptive therapy, gene therapy, T lymphocytes, major histocompatibility complex (MHC)
Abstract: Adoptive transfer of antigen-specific T cells is an attractive means to provide cancer patients with immune cells of a desired specificity and the efficacy of such adoptive transfers has been demonstrated in several clinical trials. Because the T cell receptor is the single specificity-determining molecule in T cell function, adoptive transfer of TCR genes into patient T cells may be used as an alternative approach for the transfer of tumor-specific T cell immunity. On theoretical grounds, TCR gene therapy has two substantial advantages over conventional cellular transfer, as it can circumvent the demanding process of in vitro generation of large numbers of specific immune cells and it allows the use of a set of particularly effective TCR genes in large patient groups. Conversely, TCR gene therapy may be associated with a number of specific problems that are not confronted during classical cellular therapy. Here we review our current understanding of the potential and possible problems of TCR gene therapy, as based on in vitro experiments and mouse model systems. Furthermore, we discuss the prospects of clinical application of this gene therapy approach, and the possible barriers on the route towards clinical use.
Export Options
About this article
Cite this article as:
Coccoris Miriam, de Witte A. Moniek and Schumacher N.M. Ton., Prospects and Limitations of T Cell Receptor Gene Therapy, Current Gene Therapy 2005; 5 (6) . https://dx.doi.org/10.2174/156652305774964730
DOI https://dx.doi.org/10.2174/156652305774964730 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemotherapy and Delivery in the Treatment of Primary Brain Tumors
Current Clinical Pharmacology Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugates in Oncohematology
Recent Patents on Anti-Cancer Drug Discovery Major Challenges for Gene Therapy of Thalassemia and Sickle Cell Disease
Current Gene Therapy The CCL2/CCR2 Axis in the Pathogenesis of HIV-1 Infection: A New Cellular Target for Therapy?
Current Drug Targets Recent Advances on the Enantioselective Synthesis of C-Nucleosides Inhibitors of Inosine Monophosphate Dehydrogenase (IMPDH)
Current Topics in Medicinal Chemistry Genetically Redirected T Lymphocytes for Adoptive Immunotherapy of Solid Tumors
Current Gene Therapy Influence of Tumor Microenvironment on the Distribution and Elimination of Nano-formulations
Current Drug Metabolism MicroRNA and Cancer: Tiny Molecules with Major Implications
Current Genomics Mechanisms of Drug Resistance to Vascular Endothelial Growth Factor (VEGF) Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Clinical and Genetic Features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) Syndrome
Current Molecular Medicine Caenorhabditis elegans: A Model for Studying Human Pathogen Biology
Recent Patents on Biotechnology The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
Current Drug Metabolism Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC)
Current Signal Transduction Therapy Overcoming the Drug Resistance Problem with Second-Generation Tyrosine Kinase Inhibitors: From Enzymology to Structural Models
Current Medicinal Chemistry Natural Products Homoharringtonine and Emetine Alkaloids as SARS-CoV-2 Treatment Options
Current Pharmaceutical Design Cutaneous Adverse Drug Reactions Caused by Antituberculosis Drugs
Inflammation & Allergy - Drug Targets (Discontinued) Molecular Mechanisms of Pancreatic Cancer Dissemination: The Role of the Chemokine System
Current Pharmaceutical Design Gastroduodenal Disorders in Patients with CVID Undergoing Immunoglobulin Therapy
Current Pharmaceutical Biotechnology Kinase Inhibitors as Potential Therapeutics for Acute and Chronic Neurodegenerative Conditions
Current Pharmaceutical Design IL-6 Activated JAK/STAT3 Pathway and Sensitivity to Hsp90 Inhibitors in Multiple Myeloma
Current Medicinal Chemistry